| It is an amino pyrimidine. It acts mainly in the s-phase of cell cycle when cell is undergoing DNA synthesis. It acts by inhibition of DNA polymerase
| Composition : | 100mg, 500mg, 1000mg | | Indications : | Acute non-lymphocytic leukemia of adult and paediatric patients, acute lymphocytic leukaemia chronic myelogenous leukaemia (Blast - phase), meningeal leukaemia (intra - thecal administrations) | | Contraindications : | In patients with history of hypersensitivity to the drug, pregnancy, location. | | Safety Profile : | Periodic complete blood counts are advised, use with caution patients with liver and kidney disease . | | Adverse Effects : | Bone marow depression which is dose and schedule dependent, nausea, vomiting, diarrhoea, abdominal pain, oral ulceration, hepatic dysfunction infections, paraplegia and necrotising ieukoencephalopathy occurs after intrathecal administration.
Cytarabine syndrome usually occurs 6-12 hours following drug administration. Its characterized by fever, myalgia, bone pain, maculopapular rash, conjunctivitis and malaise. It is treated with steroids. | | Drug Interactions: | Acute pancreatitis may occur in patients who had prior treatment with l-asparaginase decrease in steady state, plasma digoxin concentration, antagonize gentamicin, inhibition of fluorocytosin. | | Dosage : | In induction therepy of: Acute non lymphocytic Leukaemia - 100 mg. / m² / day continuous i.v infusion (days 1-7) or 100 mg./m² i.v every 12 hrs. In meningococcal Leukaemia:
Intrathecal - 5 mg/m²- 75 mg/m² of BSA most frequently used dose in 30 mg/m² every 4 days until CSF findings are negative cytarabine liposome:
Intrathecal - 5 mg/m²- 75 mg/m² of BSA most frequently used dose in 30 mg/m² every 4 days until CSF findings are negative cytarabine liposome | | Purity : | Not less than 99%. | |
 |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
